A new Moderna cancer vaccine, when paired with Merck's Keytruda, produced a positive clinical outcome in a mid-stage trial, the company announced this morning.
The drug combination provided a statistically significant result in stopping the recurrence of the skin cancer melanoma after surgery in patients, the Wall Street Journal reported on Tuesday morning.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.